Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | AHCY | P23526 | 2/20 | 0.31 |
| ▸ | XDH | P47989 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.31 |
| ▸ | HBB | P68871 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PNP | P00491 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | PI4KA | P42356 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11977311 | 1.00 | GDA (0.33) | GDAPDPK1AHCYXDHUSP2 | |
| SCHEMBL3328520 | 0.90 | MEN1 (0.31) | AHCY | |
| Phosphoric Acid SCHEMBL28722665 | 0.88 | ADORA2A (0.32) | GDAPARP1 | |
| Isoguanine SCHEMBL887740 | 0.80 | PARP1 (0.36) | GDAPDPK1XDHUSP2ALDH1A1 | |
| 2,6-Diaminopurine SCHEMBL24052 | 0.79 | GDA (0.48) | GDAPDPK1XDHUSP2ALDH1A1 | |
| 2,6-Diaminopurine SCHEMBL29444619 | 0.79 | GDA (0.48) | GDAPDPK1XDHUSP2ALDH1A1 | |
| SCHEMBL2526551 | 0.79 | PARP1 (0.32) | PDPK1ALDH1A1TP53HPGDPTGS1 | |
| 2,6-Diaminopurine SCHEMBL8757968 | 0.78 | GDA (0.47) | GDAPDPK1XDHUSP2ALDH1A1 | |
| 2,6-Diaminopurine SCHEMBL6423146 | 0.78 | GDA (0.47) | GDAPDPK1XDHUSP2ALDH1A1 | |
| SCHEMBL6545701 | 0.76 | GDA (0.34) | GDAPDPK1XDHUSP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1745 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| US-20260146273-A1 | METHOD FOR ONE-POT BIOSYNTHESIS OF ARABINONUCLEOSIDE, AND COMPOSITION | ASYMCHEM LIFE SCIENCE (TIANJIN) CO., LTD. (CN) | 2026-05-28 | — | — | US | claimed |
| US-12630827-B2 | Antisense oligonucleotides targeting SCN2A for the treatment of SCN1A encephalopathies | ROGCON, INC. (US) | 2026-05-19 | — | — | US | claimed |
| EP-4606904-A1 | METHOD FOR BIOSYNTHESIS OF ARABINONUCLEOSIDE BY ONE-POT METHOD, AND COMPOSITION | Asymchem Life Science (Tianjin) Co., Ltd (CN) | 2025-08-27 | — | — | EP | claimed |
| US-12391694-B2 | Process for the preparation of 2-fluoroadenine | MERCK SHARP & DOHME LLC | 2025-08-19 | — | — | US | claimed |
| US-20250186477-A1 | COMPOSITIONS COMPRISING FLUDARABINE PHOSPHATE AND METHODS OF MAKING AND USING SAME TO TREAT CANCER | Areva Pharmaceuticals Limited (IE) | 2025-06-12 | — | — | US | claimed |
| US-20250179503-A1 | METHODS OF USING OLIGOMERIC COMPOUNDS TO TREAT SCN2A-RELATED DISORDERS | PRAXIS PREC MEDICINES INC (US) | 2025-06-05 | — | — | US | claimed |
| EP-4560315-A2 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | claimed |
| US-20250146073-A1 | METHODS FOR THE TREATMENT OF SCN2A-RELATED DISORDERS | PRAXIS PREC MEDICINES INC (US) | 2025-05-08 | — | — | US | claimed |
| EP-3980554-B1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | HOFFMANN LA ROCHE (CH) | 2025-03-26 | — | — | EP | claimed |
| EP-0533825-A1 | ETHER LIPID-NUCLEOSIDE COVALENT CONJUGATES. | UNIV WAKE FOREST (US) | 1993-03-31 | — | — | EP | claimed |
| US-5180824-A | 6-AZIDO-2-FLUOROPURINE, USEFUL IN THE SYNTHESIS OF NUCLEOSIDES | BERLEX BIOSCIENCES INC. (US) | 1993-01-19 | — | — | US | claimed |
| WO-1992009604-A1 | 6-AZIDO-2-FLUOROPURINE | BERLEX BIOSCIENCES, INC. (US) | 1992-06-11 | — | — | WO | claimed |
| EP-0463999-A1 | Improvements in or relating to organic compounds | SANDOZ LTD. (CH) | 1992-01-02 | — | — | EP | claimed |
| WO-1991019726-A1 | ETHER LIPID-NUCLEOSIDE COVALENT CONJUGATES | WAKE FOREST UNIVERSITY (US) | 1991-12-26 | — | — | WO | claimed |
| EP-0456514-A1 | 2-Fluoroneplanocin A and its production | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1991-11-13 | — | — | EP | claimed |
| US-4963662-A | Fluorinated nucleosides and method for treating retrovirus infections therewith | AKADEMIE DER WISSENSCHAFTEN DER DDR (DD) | 1990-10-16 | — | — | US | claimed |
| EP-0254268-B1 | FLUORINATED NUCLEOSIDES,THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AGAINST AIDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-09-19 | — | — | EP | claimed |
| EP-0098122-B1 | PROCESSES FOR PRODUCING L-PROLINE BY FERMENTATION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1989-05-31 | — | — | EP | claimed |
| EP-0098122-A2 | Processes for producing L-proline by fermentation | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1984-01-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | HAVCR2, NR1H4, NR1H3 | GDA 4177/4885PDPK1 4288/4885AHCY 3684/4885 |
| US-12630827-B2 | Antisense oligonucleotides targeting SCN2A for the treatment of SCN1A encephalopathies | SCN1A, SCN2A, SCN1B | GDA 629/4885PDPK1 3341/4885AHCY 3140/4885 |
| US-20260146273-A1 | METHOD FOR ONE-POT BIOSYNTHESIS OF ARABINONUCLEOSIDE, AND COMPOSITION | PNP, UPP1, RNGTT | GDA 126/4885PDPK1 713/4885AHCY 487/4885 |
| US-20250179503-A1 | METHODS OF USING OLIGOMERIC COMPOUNDS TO TREAT SCN2A-RELATED DISORDERS | SCN2A, SCN1A, SCN1B | GDA 2010/4885PDPK1 2323/4885AHCY 3502/4885 |
| US-20250186477-A1 | COMPOSITIONS COMPRISING FLUDARABINE PHOSPHATE AND METHODS OF MAKING AND USING SAME TO TREAT CANCER | BCL9, PAICS, CDA | GDA 61/4885PDPK1 482/4885AHCY 292/4885 |
| US-12391694-B2 | Process for the preparation of 2-fluoroadenine | DCTD, AMPD2, CDA | GDA 37/4885PDPK1 2573/4885AHCY 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.